Archive - December 2021
FDA Approves Yusimry (adalimumab-aqvh), a Biosimilar to Humira
FDA Approves Vyvgart (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
FDA Approves Tezspire (tezepelumab) for Severe Asthma
U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease
FDA Approves Dartisla ODT (glycopyrrolate) for Use in the Treatment of Peptic Ulcer
eBook: Best of pharma 2021
Research Report: The true impact of machine failure in pharma
eBook: Smart pharma 2021